Databases: Scientists' and Organizations' Links to Industry
Return to CSPI U.S.
Non-Profit Organizations Receiving Corporate Funding 
Index of Non-Profit Organizations Receiving Corporate Funding
 
CHILDREN AND ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER/CHADD
 

"The total pharmaceutical donation support of CHADD through unrestricted educational grants comprise 22% of the total revenue, including substantial conference grants and donations. Pharmaceutical donations received by CHADD as of June 30, 2005 included support from Cephalon, Eli Lilly, McNeil, Novartis, Pfizer, Shire and UCB Pharma." (http://www.chadd.org/pdfs/2005_Annual_ Report.pdf; accessed 3/7/06)

About 20 percent of the organization’s budget in some years reportedly was underwritten by Ciba-Geigy (now Novartis), the maker of Ritalin. (“ADD - a Dubious Diagnosis?” PBS and the Merrow Report. [cited Dec. 20, 1995] http://www.add-adhd.org/ritalin_CHADD_A.D.D.html)

CHADD was reported to have received from drug companies more than $1 million in grants and services. The Drug Enforcement Administration said, “The relationship between Ciba-Geigy and CHADD raises serious concerns about CHADD’s motive in proselytizing the use of Ritalin.” (DEA, “Methylphenidate (a background paper),” October 1995, p.4.)

CHADD received about $30,000 from Novartis and ten percent of its income overall from the drug industry. (Phone call, John Heavener, CHADD, to CSPI/M. Jacobson; May 27, 1999.)

“CHADD received $748,000 from Ciba/Novartis in the period 1991 to 1994 alone.” (Law suit No. CV 1839 E (CGA); U.S. District Court, Southern District of California; Vess et al vs. Ciba-Geigy et al.; 9/13/00)


 
[Integrity in Science] [CSPI U.S.] Back to Top